Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Exclusion Criteria

• •Have diagnosis of adjustment disorder or anxiety disorder Not otherwise specified (NOS)
• •Have diagnosis of specific phobia
• •Have diagnosis of antisocial personality disorder or other Axis II Disorder
• •Have diagnosis of substance abuse disorder within 3 months of study entry
• •Have diagnosis of major depressive disorder or panic disorder within 6 months of study entry
• •Have diagnosis of PTSD, eating disorder substance dependence disorder within 12 months of study entry
• •Have diagnosis anytime during lifetime of schizophrenia or other psychotic disorder, bipolar mood disorder, Obsessive-Compulsive Disorder (OCD), psychosurgery
• •Require medication to treat GAD other than study medication
• •Failed to show improvement with past treatment for GAD
• •Excessively consume caffeine
• •Are receiving treatment with prohibited medications
• •Uncontrolled thyroid condition
• •Positive urine drug screen
• •Obese
• •Clinically significant ECG finding
• •Participating in other clinical trial
• •Clinically significant out of range lab value
• •Past exposure to rufinamide
• •Pregnant or nursing females